Arizona State Retirement System Grows Stock Holdings in Merck & Co., Inc. $MRK

Arizona State Retirement System lifted its stake in Merck & Co., Inc. (NYSE:MRK) by 0.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 686,042 shares of the company’s stock after purchasing an additional 6,296 shares during the quarter. Arizona State Retirement System’s holdings in Merck & Co., Inc. were worth $88,156,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. California State Teachers Retirement System raised its holdings in shares of Merck & Co., Inc. by 12,537.4% during the second quarter. California State Teachers Retirement System now owns 484,720,247 shares of the company’s stock valued at $62,286,552,000 after purchasing an additional 480,884,635 shares during the last quarter. BlackRock Inc. boosted its holdings in Merck & Co., Inc. by 0.5% in the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares during the last quarter. State Street Corp grew its position in Merck & Co., Inc. by 1.6% in the 4th quarter. State Street Corp now owns 120,040,168 shares of the company’s stock worth $12,737,504,000 after purchasing an additional 1,859,990 shares during the period. Wellington Management Group LLP grew its position in Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after purchasing an additional 11,156,354 shares during the period. Finally, Geode Capital Management LLC raised its stake in Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock valued at $6,307,572,000 after buying an additional 249,110 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Guggenheim raised its price target for Merck (MRK) to $170 from $146 and upgraded the shares to “buy,” implying roughly 14.5% potential upside from the referenced price. The upgrade provides a near-term positive catalyst and signals increased confidence in Merck’s growth prospects.
• Positive Sentiment: Analysts continue to point to Keytruda as the company’s primary growth engine, while Merck’s pipeline and newer products could help offset the expected impact of the 2028 patent cliff. This supports the stock’s strong performance and may reinforce the bullish outlook. Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?
• Positive Sentiment: Merck will participate in Morgan Stanley’s 24th Annual Global Healthcare Conference. Management commentary on Keytruda demand, the pipeline, and preparations for the patent expiration could provide an additional catalyst if it exceeds investor expectations. Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
• Neutral Sentiment: Reports forecast continued expansion in the global vaccine and pulmonary arterial hypertension markets, areas in which Merck participates. However, the market reports do not announce a new Merck contract, product approval, or financial forecast, limiting their immediate stock impact.
• Neutral Sentiment: Merck’s pilot with The Hashgraph Group and PwC Germany involves blockchain-based cocoa traceability. The initiative may support corporate technology and sustainability goals but is unlikely to materially affect near-term earnings. The Hashgraph Group and Merck Develop Cocoa Traceability Solution
• Negative Sentiment: With MRK near a record level and trading at a high earnings multiple, investors may require continued execution to justify the valuation. The eventual loss of Keytruda exclusivity remains the key long-term risk, while the earlier Gardasil sales downturn shows that vaccine weakness can pressure results.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares in the company, valued at $6,073,631.14. This trade represents a 63.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the transaction, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Barclays increased their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Cantor Fitzgerald reiterated a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Wells Fargo & Company increased their target price on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a report on Friday. Wolfe Research raised their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 25th. Finally, UBS Group boosted their price target on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $149.80.

Merck & Co., Inc. Stock Performance

NYSE MRK traded down $1.89 on Tuesday, hitting $148.44. 11,184,680 shares of the company traded hands, compared to its average volume of 10,784,977. The business’s 50 day moving average price is $135.06 and its 200-day moving average price is $123.73. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The company has a market capitalization of $366.23 billion, a price-to-earnings ratio of 118.75, a P/E/G ratio of 6.54 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the prior year, the business posted $2.13 earnings per share. The business’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts expect that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.’s payout ratio is currently 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.